Medical devices, healthcare technology and the business of care
PMA approval · P150004

Axium Neurostimulator System

ABBOTT MEDICAL · Decision date Feb 11, 2016

MEDTECHLEDGER EXPLANATIONP150004

What did the FDA approve?

FDA approved the Axium Spinal Modulation Neurostimulator System on February 11, 2016, under PMA number P150004. The approval covers spinal column stimulation through epidural and intra-spinal lead access to the dorsal root ganglion as an aid in managing moderate to severe chronic intractable pain of the lower limbs in adults with Complex Regional Pain Syndrome types I and II.

The statement notes that ACCURATE study subjects had failed at least two prior pharmacologic treatments from at least two drug classes and continued pharmacologic therapy during the study. It also records the 1994 IASP consensus renaming of reflex sympathetic dystrophy and causalgia as CRPS types I and II, respectively. The source does not report independent safety or effectiveness findings beyond the approval decision.

FDA approval order statement

Approval for the Axium Spinal Modulation Neurostimulator System. This device is indicated for: spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable* pain of the lower limbs in adult patients with Complex Regional Pain Syndrome (CRPS) types I and II**. * Study subjects from the ACCURATE clinical study had failed to achieve adequate pain relief from at least 2 prior pharmacologic treatments from at least 2 different drug classes and continued their pharmacologic therapy during the clinical study. ** Please note that in 1994, a consensus group of pain medicine experts gathered by the International Association for the Study of Pain (IASP) reviewed diagnostic criteria and agreed to rename reflex sympathetic dystrophy (RSD) and causalgia, as complex regional pain syndrome (CRPS) types I and II, respectively.
Regulatory pathway
Original PMA
Clinical specialty
Neurology
Decision date
Feb 11, 2016

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P150004
Regulatory pathway
Premarket approval application
Product code
PMP
Decision code
APPR
Decision date
Feb 11, 2016
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Dorsal root ganglion stimulator for pain relief.

Product code
PMP
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P150004 received

    Application receipt date recorded by FDA.

  2. P150004 · FDA decision

    APPR

  3. P150004/S101 · Related supplement

    Dorsal Root Ganglion Stimulation (DRG) EPG

Timeline entries are records held by MedtechLedger for P150004. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150004

Product / regulatory recordCompanyPathwayDecision dateSource
Proclaim DRG IPGP150004/S100
ABBOTT MEDICALPMA supplementSep 23, 2026FDA
ABBOTT MEDICALPMA supplementOct 28, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
6901 Preston Rd., Plano, TX, 75024

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records